The UTMB NIAID Clinical Proteomics Center for Infectious Disease and Biodefense offers established proteomic expertise to support the discovery, qualification and verification of clinical protein biomarkers for diseases caused by NIAID Category A-C pathogens and emerging and re-emerging infectious disease pathogens. This Center draws on existing resources in the Sealy Center for Molecular Medicine, the UTMB Proteomics Center, the UTMB Bioinformatics Program, and the Center for Biodefense and Emerging Infectious Diseases (CBEID). A clinical proteomics pipeline draws in unique intellectual expertise in NIAID Category A-C pathogens and an international network of contacts and collaborators, including, for example, the NIAID Region V Centers of Excellence for Biodefense and Emerging Infectious Diseases (WRCE) and the WHO Reference Library on Arbovirus located at UTMB.
The UTMB CPC Center is divided into separate Technical Teams to maximally align with the major scientific and technical objectives of this contract. The major pathway for information and sample flow is indicated by the green arrows. Clinical studies will be developed via the Clinical Proteomics Pipeline and evaluated by our Scientific Working Group (SWG).
The major activities of the Administative Team are to:
The Sample Repository/Data Warehouse Team is responsible for the data archival and tracking of samples submitted to the UTMB CPC. The aims of the Sample Repository/Data Warehouse Team are to:
The Discovery Team is co-directed by John Wiktorowicz, PhD and Alexander Kurosky, PhD, nationally recognized investigators in proteomics and technology development. The aims of the Proteomics Discovery Team are to:
The Bioinformatics Team is directed by Bruce Luxon, PhD, Director of the UTMB Bioinformatics Program. He will be supported by statisticians and programmers to identify groups (panels) of disease-informative biomarkers and construct models that associate these biomarkers with clinical outcome. The aims of the Bioinformatics Team are to:
The Qualification and Verification Team is directed by Yingxin Zhao. The team apply independent methods to confirm protein identification and to allow for larger verification studies of candidate biomarkers. The aims of the Qualification and Verification Team are to: